Datopotamab Deruxtecan, often abbreviated as DATO, represents a important advancement within targeted cancer therapy. This innovative antibody-drug conjugate combines an monoclonal antigen specifically focused on HER2 https://lawsonfcnt964974.pointblog.net/datopotamab-deruxtecan-the-promising-antibody-drug-compound-92097694